Drug Profile
Rilimogene galvacirepvec-rilimogene glafolivec - BN ImmunoTherapeutics
Alternative Names: PROSTVAC; PROSTVAC-F; PROSTVAC-V; PROSTVAC-VF-TRICOM; PSA-TRICOM; Rilimogene gamvacirepvec-rilimogene glafolivec; Rilimogene-glafolivec-rilimogene-galvacirepvec; Vaccinia PSA TRICOM-fowlpox PSA TRICOMLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator National Cancer Institute (USA)
- Developer BN ImmunoTherapeutics; National Cancer Institute (USA); University of California at San Francisco
- Class Antineoplastics; Cancer vaccines; Gene therapies; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 28 Apr 2023 Adverse events data from a phase II trial in Prostate cancer presented at the 118th Annual Meeting of the American Urological Association (AUA-2023)
- 26 Oct 2022 National Cancer Institute completes a phase-II clinical trials in Prostate cancer (Combination therapy, Hormone-refractory, Late-stage disease, Metastatic disease) in USA (SC) (NCT01867333)
- 25 Jul 2022 Bristol-Myers Squibb and Washington University School of Medicine completes a phase I trial in Prostate cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in USA (SC) (NCT03532217)